{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:19Z","timestamp":1786119559768,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/01.cad.0000390768.93282.65","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T00:29:23Z","timestamp":1292632163000},"page":"S15-S20","source":"Crossref","is-referenced-by-count":8,"title":["Knowledge of hereditary renal cancer syndromes"],"prefix":"10.1097","volume":"22","author":[{"given":"Jes\u00fas","family":"Garc\u00eda-Donas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers.","volume":"361","author":"Fong","year":"2009","journal-title":"NEngl J Med"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0022-5347(01)66674-6","article-title":"Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma, and no renal disease: clinical implications.","volume":"154","author":"Walther","year":"1995","journal-title":"J Urol"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00005392-199909010-00004","article-title":"Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma.","volume":"162","author":"Walther","year":"1999","journal-title":"J Urol"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archopht.125.2.239","article-title":"Genotype phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis.","volume":"125","author":"Wong","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.surg.2007.09.012","article-title":"Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs).","volume":"142","author":"Blansfield","year":"2007","journal-title":"Surgery"},{"key":"R7-4-20210203","first-page":"480","article-title":"Endolymphatic sac tumors in von Hippel-Lindau disease.","volume":"100","author":"Choo","year":"2004","journal-title":"JNeurosurg"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","article-title":"The genetic basis of cancer of the kidney.","volume":"170","author":"Linehan","year":"2003","journal-title":"J Urol"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2796.1998.00336.x","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease.","volume":"243","author":"Neumann","year":"1998","journal-title":"J Intern Med"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1128\/MCB.18.2.732","article-title":"Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins, BC and Cul2.","volume":"18","author":"Lonergan","year":"1998","journal-title":"Mol Cell Biol"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the -domain of the von Hippel-Lindau protein.","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K","article-title":"Improved detection of germ line mutations in the on Hippel-Lindau disease tumor suppressor gene.","volume":"12","author":"Stolle","year":"1998","journal-title":"Hum Mutat"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.ju.0000132127.79974.3f","article-title":"The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease.","volume":"172","author":"Duffey","year":"2004","journal-title":"J Urol"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma TARGET study group.","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon- in metastatic renal-cell carcinoma.","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.291.8.943","article-title":"Antiangiogenic therapy for von Hippel-Lindau disease.","volume":"291","author":"Madhusudan","year":"2004","journal-title":"JAMA"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1200\/JCO.2005.01.184","article-title":"Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.","volume":"23","author":"Schuch","year":"2005","journal-title":"J Clin Oncol"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.","volume":"94","author":"Jimenez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-5347(17)35015-2","article-title":"Hereditary papillary renal cell carcinoma.","volume":"151","author":"Zbar","year":"1994","journal-title":"J Urol"},{"key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","article-title":"Novel mutations of the MET proto-oncogene in papillary renal carcinomas.","volume":"18","author":"Schmidt","year":"1999","journal-title":"Oncogene"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","article-title":"A phase I study of foretinib: a multi-targeted inhibitor of c-MET and vascular endothelial growth factor receptor 2.","volume":"16","author":"Eder","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R26-4-20210203","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1200\/jco.2008.26.15_suppl.5103","article-title":"A phase II study of the dual METVEGFR2 inhibitor XL880 in patients with papillary renal carcinoma (PRC) abstract.","volume":"26","author":"Srinivasan","year":"2008","journal-title":"J Clin Oncol"},{"key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1001\/archderm.1977.01640120042005","article-title":"Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons.","volume":"113","author":"Birt","year":"1977","journal-title":"Arch Dermatol"},{"key":"R28-4-20210203","first-page":"393","article-title":"Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome.","volume":"11","author":"Zbar","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/00000478-200212000-00002","article-title":"Renal tumors in the Birt-Hogg-Dube syndrome.","volume":"26","author":"Pavlovich","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome.","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"key":"R31-4-20210203","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2009.14","article-title":"The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis.","volume":"28","author":"Hartman","year":"2009","journal-title":"Oncogene"},{"key":"R32-4-20210203","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1470-2045(09)70188-3","article-title":"European BHD Consortium Birt-Hogg-Dube syndrome: diagnosis and management.","volume":"10","author":"Menko","year":"2009","journal-title":"Lancet Oncol"},{"key":"R34-4-20210203","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2340\/0001555553409416","article-title":"Cutaneous leiomyomata with uterine leiomyomata.","volume":"53","author":"Reed","year":"1973","journal-title":"Acta derm Venereol"},{"key":"R35-4-20210203","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R36-4-20210203","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germ line mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"R38-4-20210203","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/MCB.00483-09","article-title":"Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor-1 stabilization by glucose-dependent generation of reactive oxygen species.","volume":"29","author":"Sudarshan","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R39-4-20210203","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer.","volume":"177","author":"Grubb","year":"2007","journal-title":"J Urol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.cad.0000390768.93282.65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:50:35Z","timestamp":1786042235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201101001-00004"}},"subtitle":["a pending issue for oncologists"],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":34,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cad.0000390768.93282.65","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}